{"id":103190,"date":"2026-05-25T10:11:00","date_gmt":"2026-05-25T10:11:00","guid":{"rendered":"https:\/\/flamenet.io\/2026\/05\/25\/pierre-fabre-laboratories-receives-chmp-positive-opinion-for-braftovi-encorafenib-in-combination-with-cetuximab-and-folfox-fluorouracil-leucovorin-and-oxaliplatin-for-the-first-line-treatm\/"},"modified":"2026-05-25T10:11:00","modified_gmt":"2026-05-25T10:11:00","slug":"pierre-fabre-laboratories-receives-chmp-positive-opinion-for-braftovi-encorafenib-in-combination-with-cetuximab-and-folfox-fluorouracil-leucovorin-and-oxaliplatin-for-the-first-line-treatm","status":"publish","type":"post","link":"https:\/\/flamenet.io\/2026\/05\/25\/pierre-fabre-laboratories-receives-chmp-positive-opinion-for-braftovi-encorafenib-in-combination-with-cetuximab-and-folfox-fluorouracil-leucovorin-and-oxaliplatin-for-the-first-line-treatm\/","title":{"rendered":"Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic color &#8211; PR Newswire"},"content":{"rendered":"<p><a href=\"https:\/\/news.google.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?oc=5\" target=\"_blank\">Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic color<\/a>&nbsp;&nbsp;<font color=\"#6f6f6f\">PR Newswire<\/font><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI\u00ae (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of&#8230; <a href=\"https:\/\/flamenet.io\/2026\/05\/25\/pierre-fabre-laboratories-receives-chmp-positive-opinion-for-braftovi-encorafenib-in-combination-with-cetuximab-and-folfox-fluorouracil-leucovorin-and-oxaliplatin-for-the-first-line-treatm\/\" class=\"read-more\">[more]<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[68],"tags":[],"class_list":["post-103190","post","type-post","status-publish","format-standard","hentry","category-opinion"],"_links":{"self":[{"href":"https:\/\/flamenet.io\/api\/wp\/v2\/posts\/103190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flamenet.io\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flamenet.io\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/comments?post=103190"}],"version-history":[{"count":0,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/posts\/103190\/revisions"}],"wp:attachment":[{"href":"https:\/\/flamenet.io\/api\/wp\/v2\/media?parent=103190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/categories?post=103190"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/tags?post=103190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}